Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine

Abstract #802036: Safety and Efficacy of Faster Acting Insulin Aspart in People With Type 2 Diabetes and Chronic Kidney Disease: A Real-World Study from India

Endocrine Practice ◽

10.1016/s1530-891x(20)39507-0 ◽

2020 ◽

Vol 26 ◽

pp. 101-102

Author(s):

Supratik Bhattacharyya

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Real World ◽

Insulin Aspart ◽

Safety And Efficacy ◽

Acting Insulin

Download Full-text

Abstract #1151: Lower Risk of Hypoglycemia and Less Health Care Utilization in Basal Insulintreated Patients with Type 2 Diabetes (T2D) After Switching to Insulin Glargine 300 UNITS/ML (GLA-300) VS Other Basal Insulins in Real-World Clinical Settings

Endocrine Practice ◽

10.1016/s1530-891x(20)44281-8 ◽

2017 ◽

Vol 23 ◽

pp. 317-318

Author(s):

Fang Liz Zhou ◽

Fen Ye ◽

Vineet Gupta ◽

Rishab Gupta ◽

Jennifer Sung ◽

...

Keyword(s):

Type 2 Diabetes ◽

Health Care ◽

Health Care Utilization ◽

Insulin Glargine ◽

Real World ◽

Lower Risk ◽

Care Utilization ◽

Clinical Settings

Download Full-text

Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching From Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—DELIVER D+ Subgroup Analyses

Diabetes ◽

10.2337/db18-1057-p ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 1057-P

Author(s):

SEAN D. SULLIVAN ◽

TIMOTHY S. BAILEY ◽

RONAN ROUSSEL ◽

FANG L. ZHOU ◽

ZSOLT BOSNYAK ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Clinical Outcomes ◽

Real World ◽

Insulin Detemir ◽

Insulin Degludec ◽

Subgroup Analyses

Download Full-text

2327-PUB: Real-World Patient-Reported Outcomes (PROs) with Insulin Glargine 300 U/ml (Gla-300) in Basal Bolus-Treated People with Type 2 Diabetes (T2DM): The MAGE Study

Diabetes ◽

10.2337/db19-2327-pub ◽

2019 ◽

Vol 68 (Supplement 1) ◽

pp. 2327-PUB ◽

Cited By ~ 1

Author(s):

ANN A. VERHAEGEN ◽

ANDRÉ SCHEEN ◽

KATHY C. ALEXANDRE ◽

JACQUES BRUHWYLER ◽

IDES M. COLIN

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Real World ◽

Patient Reported Outcomes ◽

Patient Reported ◽

Basal Bolus

Download Full-text

2192-PUB: Treatment Satisfaction in People with Type 2 Diabetes (T2D) Receiving Basal Insulin (BI): Results from Real-World Studies and Randomized Controlled Trials (RCTs) with Insulin Glargine 300 U/mL (Gla-300)

Diabetes ◽

10.2337/db20-2192-pub ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 2192-PUB

Author(s):

STEWART B. HARRIS ◽

FRANK J. SNOEK ◽

LUIGI MENEGHINI ◽

FELIPE LAUAND ◽

JUKKA WESTERBACKA ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Randomized Controlled Trials ◽

Real World ◽

Basal Insulin ◽

Treatment Satisfaction ◽

Controlled Trials ◽

Randomized Controlled

Download Full-text

Clinical Research of Insulin Glargine U300 basal‐bolus therapy and Insulin Degludec/Aspart Co‐Formulation in Type 2 Diabetes Mellitus: A Real World Experience (CRIGDA Study)

International Journal of Clinical Practice ◽

10.1111/ijcp.14377 ◽

2021 ◽

Author(s):

Savas Volkan Kisioglu ◽

Ahmet Suat Demir ◽

Damla Tufekci ◽

Yasemin Emur Gunay ◽

Hulya Coskun ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Clinical Research ◽

Insulin Glargine ◽

Real World ◽

Insulin Degludec ◽

Basal Bolus

Download Full-text

Impact of Initiating Insulin Glargine Disposable Pen Versus Vial/Syringe on Real-World Glycemic Outcomes and Persistence Among Patients with Type 2 Diabetes Mellitus in a Large Managed Care Plan: A Claims Database Analysis

Diabetes Technology & Therapeutics ◽

10.1089/dia.2013.0312 ◽

2014 ◽

Vol 16 (9) ◽

pp. 567-575 ◽

Cited By ~ 14

Author(s):

Lin Xie ◽

Steve Zhou ◽

Brett W. Pinsky ◽

Erin K. Buysman ◽

Onur Baser

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Insulin Glargine ◽

Real World ◽

Care Plan ◽

Database Analysis ◽

Claims Database ◽

Glycemic Outcomes

Download Full-text

Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2019.04.012 ◽

2019 ◽

Vol 43 (7) ◽

pp. 504-509.e1 ◽

Cited By ~ 2

Author(s):

Alexander Abitbol ◽

Ruth E. Brown ◽

Dishay Jiandani ◽

Luc Sauriol ◽

Ronnie Aronson

Keyword(s):

Type 2 Diabetes ◽

Health Outcomes ◽

Insulin Glargine ◽

Real World ◽

Diabetes Patient ◽

World Health ◽

Patient Registry

Download Full-text

Does device matter and at what cost? real-world comparative study of insulin glargine treatment using disposable pen versus vial/syringe in medicaid patients with type-2 diabetes mellitus

Value in Health ◽

10.1016/j.jval.2013.03.777 ◽

2013 ◽

Vol 16 (3) ◽

pp. A156 ◽

Cited By ~ 1

Author(s):

Z. Cao ◽

E. Thomson ◽

Z. Ling ◽

R. Miao ◽

W. Wei

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Comparative Study ◽

Insulin Glargine ◽

Real World

Download Full-text

Review for "Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: DELIVER Naïve D real‐world study"

10.1111/dom.13793/v1/review3 ◽

2019 ◽

Author(s):

Fernando Gomez-Peralta

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Insulin Glargine ◽

Real World ◽

Insulin Degludec

Download Full-text